Literature DB >> 1324637

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.

M J Rybak1, E M Bailey, K C Lamp, G W Kaatz.   

Abstract

The pharmacokinetics and bactericidal killing rates (BR) of daptomycin (D) and vancomycin (V) in 12 intravenous drug abusers (6 treated with daptomycin and 6 treated with vancomycin) were evaluated. Pharmacokinetic parameters were determined from multiple serum samples drawn at steady state over a 12-h dosing interval after intravenous infusions of 3 mg of D per kg of body weight and 1,000 mg of V. The BRs were determined from the 1- and 6-h serum samples by using four isolates of Staphylococcus aureus (three methicillin susceptible and one methicillin resistant) obtained from the patients enrolled in the study. Peak serum daptomycin concentrations were lower and volumes of distribution were higher than reported in healthy volunteers. Although not statistically different, D clearance was 22% higher than reported in healthy volunteers. V pharmacokinetics were similar to those reported in previous studies. Daptomycin's BRs, although comparable to those of V in patients' serum, were significantly decreased compared with those found in broth. This may be related to the high degree of protein binding of D (93% versus 50% for V). Conversely, the BRs of V in serum were significantly greater than those in broth. The BRs of D and V in broth were greater when killing curves were performed with test strains in logarithmic versus stationary-phase growth. The ability to kill organisms in stationary phase may be an important factor in determining the performance of an antibiotic in deep-seated infections such as endocarditis.3+

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324637      PMCID: PMC188844          DOI: 10.1128/AAC.36.5.1109

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Suboptimal effect of daptomycin in the treatment of bacteremias.

Authors:  M W Garrison; J C Rotschafer; K B Crossley
Journal:  South Med J       Date:  1989-11       Impact factor: 0.954

2.  Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

Authors:  W E Alborn; N E Allen; D A Preston
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Noncompartmental determination of the steady-state volume of distribution during multiple dosing.

Authors:  I L Smith; J J Schentag
Journal:  J Pharm Sci       Date:  1984-02       Impact factor: 3.534

4.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

5.  Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Authors:  H Hanberger; L E Nilsson; R Maller; B Isaksson
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

6.  Synergistic bactericidal activity of rat serum with vancomycin against enterococci.

Authors:  M J Gold; J Calmon; M Wendeler; M E Levison; C C Johnson
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

7.  Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.

Authors:  J P Flandrois; G Fardel; G Carret
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

9.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.

Authors:  E M Bailey; M J Rybak; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; V N Reddy; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

View more
  28 in total

1.  In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia.

Authors:  F Pea; M Crapis; P Cojutti; M Bassetti
Journal:  Infection       Date:  2013-07-25       Impact factor: 3.553

4.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Activity of serum concentrations of daptomycin vs. vancomycin against vancomycin-susceptible and resistant Enterococcus faecium in the presence of albumin physiological concentrations: an in vitro pharmacodynamic simulation.

Authors:  L Alou; L Aguilar; M J Giménez; M Torrico; D Sevillano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-21       Impact factor: 3.267

6.  Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.

Authors:  Holenarasipur R Vikram; Nancy L Havill; Laura M Koeth; John M Boyce
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 7.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 9.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.

Authors:  N Mobarakai; J M Quale; D Landman
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.